InvestorsHub Logo
Post# of 253152
Next 10
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 209848

Monday, 08/06/2018 4:17:39 PM

Monday, August 06, 2018 4:17:39 PM

Post# of 253152
AGN, EDIT announce mutual opt-ins on EDIT-101:

https://www.prnewswire.com/news-releases/allergan-and-editas-medicine-announce-exercise-of-options-to-jointly-develop-crispr-genome-editing-experimental-medicine-edit-101-300692493.html

…[Allergan] has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

Under the terms of the option agreement signed in March 2017 [#msg-129491806], Allergan has paid Editas Medicine a fee of $15 million in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25 million from Allergan upon acceptance of an investigational new drug (IND) application for EDIT-101 by the Food & Drug Administration (FDA).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.